Researchers test off-patent antibiotics to treat MRSA
MRSA has become the most common skin infection that is found within the United States, and can end in surgical procedures, hospitalization, bacteria in the blood stream, and even death.
Health professionals have not yet determined a standard treatment for MRSA. Two older antibiotics, TMP-SMX and clindamycin, neither of which is patented, have been recommended for CA-MRSA treatments. Another antibiotic was theorized to have better results.
Researchers sought to answer this question by testing TMP-SMX and clindamycin in 466 adults and children who had uncomplicated skin infections that lasted 10 days. With TMP-SMX, the cure rate was 88.2 percent. For clindamycin, the cure rate was 89.5 percent. Both of these drugs had comparable side effects, as results show that uncomplicated skin infections contracted outside a hospital environment could be successfully and cheaply treated with either TMP-SMX or clindamycin.
The research, funded by the National Institute of Allergy and Infectious Diseases branch of the National Institutes of Health, could benefit many individuals who are most often impacted by MRSA or CA-MRSA, including athletes, students, daycare-age children, prison inmates and military personnel.